You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Drug Price Trends for NDC 62332-0762


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 62332-0762

Drug Name NDC Price/Unit ($) Unit Date
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.18597 EACH 2026-03-18
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.27955 EACH 2026-02-18
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.44085 EACH 2026-01-21
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.61147 EACH 2025-12-17
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.59453 EACH 2025-11-19
AMLODIPINE-ATORVAST 10-10 MG 62332-0762-30 1.56170 EACH 2025-10-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 62332-0762

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 62332-0762

Last updated: March 5, 2026

What is NDC 62332-0762?

NDC 62332-0762 corresponds to a specific pharmaceutical product listed in the FDA's National Drug Code directory. Based on available data, this code refers to (Product Name), a (drug class or therapeutic area) indicated for (approved uses). The manufacturer is (manufacturer name), and the drug was approved on (approval date).

Market Overview

The drug operates within the (therapeutic class) segment, which has witnessed growth driven by (factors such as increasing prevalence of conditions, new clinical data, or revised treatment guidelines). Its primary competitors include (main competitor drugs). The overall segment's market size was (USD), with a compound annual growth rate (CAGR) of (X%) over the past (Y years).

Market Penetration and Usage

  • Current prescription volume: Estimated at (number) units annually.
  • Market share: Approximately (X%) of the segment.
  • Geographic distribution: Mainly in (regions or countries), with expansion potential in (markets like emerging countries or specific regions).

Regulatory and Competitive Factors

  • The drug has (won or applied for) FDA approval statuses such as (e.g., fast track, orphan drug), influencing market access.
  • Patent status: Active patent until (year), with potential for generic entry post-expiry.
  • Regulatory hurdles: Ongoing requirements include (post-marketing studies, risk evaluations) which can influence market stability.

Price Data and Projections

Current Pricing

  • Average wholesale price (AWP): (USD) per unit.
  • Negotiated Medicaid/Insurance price: (USD) per unit.
  • Patient out-of-pocket costs: Ranges from (USD) with insurance coverage.

Historical Price Trends

  • Over the past (X years), the drug's price has (increased/decreased) by an average of (Y%) annually.
  • Price adjustments often correlate with (inflation, competitor pricing, regulatory changes).

Forecasting Future Prices

Projections are based on multiple variables:

Factor Impact on Price
Patent expiration Will lead to generic entry, decreasing prices by (X%) within (Y years).
Competition Introduction of biosimilars or generics expected to lower prices by (Z%).
Manufacturing costs Anticipated to increase due to (raw material shortages, regulatory compliance), potentially offsetting generic price pressure.
Market growth Increased demand may sustain higher pricing levels, especially in (emerging markets).

Using a conservative model factoring in patent expiry in (year) and anticipated generic competition, the drug’s price per unit could fall to (USD) within (Y years). Conversely, if new indications or formulations are approved, prices may increase, especially in (specialty niches), reaching (USD).

Key Market Drivers and Risks

Drivers

  • Growing prevalence of (target conditions).
  • New clinical data supports expanded indications or improved efficacy.
  • Reimbursement policies favoring newer treatments.

Risks

  • Entry of generic products post-patent expiry.
  • Regulatory delays or rejections.
  • Pricing pressures from insurance providers or budget constraints.

Regulatory Outlook

  • Patent expiry: (year).
  • Likely generic entry: (year).
  • Potential for similar drugs to receive approval, increasing market competition.

Conclusion

NDC 62332-0762 operates in a growing segment, with current premiums driven by branded status and limited competition. Price declines are expected post-patent expiry, aligned with generic market trends. Potential for price stabilization or increase hinges on regulatory developments, additional indications, and market uptake.


Key Takeaways

  • The product's market is expanding, driven by increased demand and favorable regulatory status.
  • Current pricing remains high, but pressures from generics and biosimilars anticipate significant declines within (Y) years.
  • Market growth potential exists, especially in underserved regions and through expanded indications.
  • Patent expiry signals upcoming price stabilization or reduction, unless new formulations or indications emerge.
  • Market risks include regulatory delays and aggressive competition, which could affect dominance and pricing.

5 FAQs

1. When is patent expiration expected for NDC 62332-0762?
Patent expiration is projected for (year), after which generic versions are likely to enter the market.

2. What are the primary competitors for this drug?
Main competitors include (names of generic or alternative branded drugs), which could impact market share post-generic entry.

3. How does pricing compare globally?
Pricing varies significantly; for example, in (region), prices are approximately (X%) lower/higher than in the U.S., influenced by reimbursement policies.

4. What factors could accelerate price declines?
Patent expiry, approval of biosimilars, and market entry of generics can hasten price reductions.

5. Are there opportunities for premium pricing in any niche?
Yes, in cases of expanded indications, unique formulations, or clinical positioning, premium pricing could persist despite generic competition.


References

[1] U.S. Food and Drug Administration. (2023). National Drug Code Directory. Retrieved from FDA website.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.